Floatz logo

LEVODOPA

Stroke

University Hospital, Basel, SwitzerlandSmall moleculePhase 4 / ApprovedActive
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
65/ 100

Competitive context

132 Active assets in the Stroke cohort.

Asset / SponsorPhaseRating
Aggrenox
Boehringer Ingelheim
Phase 4BBB
INCOBOTULINUMTOXINA
Parc de Salut Mar
Phase 4BBB
ATENOLOL
Northern California Institute of Research and Education
Phase 4BBB
Dextromethorphan
University of Florida
Phase 4BBB
Rivaroxaban
China National Center for Cardiovascular Diseases
Phase 4BBB

View all 50 →

Same molecule, other indications

LEVODOPA is also rated in:

drug-induced dyskinesiaDormant
A
Indicative ·
80 / 100
View asset →
Parkinson diseaseDormant
BBB
Indicative ·
75 / 100
View asset →
movement disorderDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →